NASDAQ
11.13USD
+0.03 (+0.27%)
Market cap
994M
P/E
—
EPS
—
Beta
2.24
52W range
2.865-11.405
Day range
11.13–11.13
Open
11.13
Prev close
11.10
Volume
10.3M
Avg volume
5.7M
Dividend
0.00
IPO
2021-06-17
No scored news tagged VERV or its network in the window yet.
Show more VERV articles →Verve Therapeutics, Inc. is a biotechnology firm dedicated to pioneering gene-editing treatments for individuals afflicted with cardiovascular diseases. Their flagship experimental therapy, VERVE-101, represents a singular gene-editing intervention engineered to irreversibly inactivate the PCSK9 gene within the liver. The company is also progressing with an ANGPTL3 program, which similarly aims to permanently switch off the ANGPTL3 gene in the liver. To support its endeavors, Verve maintains several key partnerships, including a collaboration and licensing pact with Beam Therapeutics Inc., a development and option agreement with Acuitas Therapeutics, Inc., and a Cas9 gene-editing technology license from The Broad Institute and the President and Fellows of Harvard College. Incorporated in 2018 and headquartered in Cambridge, Massachusetts, the organization operated under the name Endcadia, Inc. until its rebranding to Verve Therapeutics, Inc. in January 2019.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Verve Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Verve Therapeutics, Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
